BioSpace News Archive

Nektar Therapeutics has entered into a financing and co-development collaboration with SFJ Pharmaceuticals which will advance the development of investigational CD122-preferential IL-2–pathway agonist bempegaldesleukin for head and neck cancer.

The U.S. FDA granted Amgen Priority Review for sotorasib for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), after at least one previous systemic therapy.

The Foundation will offer funding for development of the therapy.

Currently, research is still ongoing with regards to the link between COVID and POTS. However, this increasing number of cases and the unfamiliarity of COVID’s long-lasting effects leave a lot more for the researchers to unmask.

10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provides outlook for full year 2021.

Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer and other serious diseases, today announced that it has commenced an underwritten public offering of its common stock.

- Provention Bio to receive $6 million upfront payment; up to $11.5 million in research, development and manufacturing funding; and up to $172 million in potential development, regulatory and commercial milestone payments -

Heron Therapeutics, Inc. announced that Barry Quart, Pharm.D., Chairman and Chief Executive Officer of Heron Therapeutics, will present at the following virtual investor conferences:

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced that the company will participate in two upcoming investor conferences. 10 th Annual SVB Leerink Global Healthcare Conference

Globus Medical, Inc., a leading musculoskeletal solutions company, announced its financial results for the fourth quarter and year ended December 31, 2020.